



European Monitoring Centre
for Drugs and Drug Addiction

EMCDDA activities related to infectious diseases among people who inject drugs

Roland Simon, Klaudia Palczak, EMCDDA
Luxembourg, 6 July 2015

European Drug Report 2015

- Trends by substance
- Drug related harm
- Interventions

Activities in 2015

European Drug Report (EDR) package



Overview on trends



emcdda

**20 years
of monitoring**

- Overall decrease in heroin problems and related harms, although supply indicators raise new concerns
- Treatment systems and law enforcement efforts — cannabis increasingly important
- Emergence of new drugs continues and monitoring of use, harms and responses needs to keep pace
- Market competition and innovation drive purity and potency increases, with new virtual marketplaces emerging.



emcdda.europa.eu

Heroin market

Drop in seizures from 2009 and long term decline in quantities, but increases for Turkey


Recent upturn in heroin purity

Heroin seizures by number and quantity




Over 50 % of problem opioid users receive treatment

Percentage of problem opioid users receiving substitution treatment (estimate)



NB: Data displayed as point estimates and uncertainty intervals.


Trends in number of clients in OST



Trends in treatment of opioid problems


New heroin clients more than halved from 2007 to 2013

Trends in first-time entrants




Opioid users in treatment

2006




2013




Cocaine


Quantity of cocaine seized




Last year use of cocaine



Number of seizures




Treatment requests




Amphetamines


Amphetamines: Seizures



Methamphetamines: Seizures




NPS reported



Cannabinoids Cathinones Opioids
Phenethylamines Piperazines Arylamines
Tryptamines Other substances

HIV diagnoses fall after outbreaks

Newly diagnosed HIV cases related to injecting drug use




Responses to outbreak in Greece and Romania



Hepatitis C

HCV antibody prevalence among injecting drug users



HCV antibody levels among drug injectors vary between 14 % and 84 %

New diagnostic tools and medications available


High treatment costs

Overdose deaths


Over 6 100 deaths in 2013

Recent increases a concern


Trends in overdose deaths



Drug-induced mortality rates among adults



Preventing drug overdoses and deaths



Drug consumption rooms

POD

- 70+ supervised facilities
- ‘Local’ response to reduce harms, deaths and connect users with services
- Types: integrated, specialised and mobile facilities



Evidence is core: Best Practice Portal



European Monitoring Centre
for Drugs and Drug Addiction

- [Data](#)
- [Countries](#)
- [Topics \(A-Z\)](#)
- [Our activities](#)
- [Best practice](#)**
- [Publications](#)
- [News and events](#)
- [About](#)

Home / Best practice

Best practice portal

About the portal

The Best practice portal is a resource for professionals, policymakers and researchers in the areas of drug-related prevention, treatment, harm reduction and social reintegration. The portal concentrates on illicit drugs and polydrug use and has a clear European focus. It is continuously updated as information and research on interventions emerges.

[More information »](#)

[Overview](#)

[Evidence](#)

[Guidelines](#)

[Examples](#)

[Tools](#)

[News](#)

[Collaborations](#)

Evidence

Peruse the latest evidence to find out what works (and what doesn't) in the areas of drug prevention, treatment, harm reduction and social reintegration.

Guidelines

Many countries have guidelines and standards for drug-related interventions, aimed at improving their quality and effectiveness. View them here.

Examples

A searchable database of real-life implementations of drug-related interventions in Europe, designed to help professionals and policy-makers.

Tools

An online archive of freely available instruments (e.g. questionnaires) for evaluating prevention, treatment and harm reduction interventions.

Collaborations and partnerships in best-practice



emcdda.europa.eu

Major EMCDDA activities in 2015

1. European Drugs Report package 2014
 - Lisbon launch
 - National launches
2. EMCDDA publications
 - *Insight* publication on HCV treatment
 - *Insight* publication on Naloxone
3. Key EMCDDA experts meetings
 - June – DRID Expert meeting
 - September – 20 Years Monitoring
 - September – Lisbon Addiction 2015 (incl. sponsored session on HCV)
4. Joint ECDC-EMCDDA:
 - Latvia Common Mission report
 - Dublin monitoring
 - Wound botulism
5. Other collaborations
 - JA on HIV
 - JA on Harm reduction
6. UN special session on drugs in 2016

A close-up photograph of a white lotus flower. The petals are large and white, with some showing a light purple or blue hue near the base. The central focus is the green stem, which has a prominent, brown, textured, bulbous structure at its base, likely a developing seed pod or a specific part of the stem. The background is softly blurred, showing more of the same flowers.

www.emcdda.europa.eu

Thank you!